Selected research
Industry Research
Neuroendocrine Tumors (NETs) Treatment Industry Research Report 2026
Market perspective
The global Neuroendocrine Tumors (NETs) Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Neuroendocrine Tumors (NETs) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Neuroendocrine Tumors (NETs) Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Neuroendocrine Tumors (NETs) Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Neuroendocrine Tumors (NETs) Treatment include Novartis AG, Pfizer, Inc, Progenics Pharmaceuticals, IpsenPharma, Hutchison MediPharma Limited, Boehringer Ingelheim International, AVEO Oncology and Advanced Accelerator Applications, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Neuroendocrine Tumors (NETs) Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuroendocrine Tumors (NETs) Treatment Market by Company
Novartis AG
Pfizer, Inc
Progenics Pharmaceuticals
IpsenPharma
Hutchison MediPharma Limited
Boehringer Ingelheim International
AVEO Oncology
Advanced Accelerator Applications
Neuroendocrine Tumors (NETs) Treatment Segment by Type
Somatostatin Analogs (SSAs)
Targeted Therapy
Other
Neuroendocrine Tumors (NETs) Treatment Segment by Application
Hospitals
Clinics
Other
Neuroendocrine Tumors (NETs) Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumors (NETs) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumors (NETs) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumors (NETs) Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neuroendocrine Tumors (NETs) Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neuroendocrine Tumors (NETs) Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neuroendocrine Tumors (NETs) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Somatostatin Analogs (SSAs)
- Targeted Therapy
- Other
Applications
- Hospitals
- Clinics
- Other
Companies covered
- Novartis AG
- Pfizer, Inc
- Progenics Pharmaceuticals
- IpsenPharma
- Hutchison MediPharma Limited
- Boehringer Ingelheim International
- AVEO Oncology
- Advanced Accelerator Applications
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size (2021-2032)
- 2.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales (2021-2032)
- 2.2.3 Global Neuroendocrine Tumors (NETs) Treatment Market Average Price (2021-2032)
- 2.3 Neuroendocrine Tumors (NETs) Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Somatostatin Analogs (SSAs)
- 2.3.3 Targeted Therapy
- 2.3.4 Other
- 2.4 Neuroendocrine Tumors (NETs) Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neuroendocrine Tumors (NETs) Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Neuroendocrine Tumors (NETs) Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neuroendocrine Tumors (NETs) Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neuroendocrine Tumors (NETs) Treatment, Product Type & Application
- 3.8 Global Manufacturers of Neuroendocrine Tumors (NETs) Treatment, Established Date
- 3.9 Global Neuroendocrine Tumors (NETs) Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Pfizer, Inc
- 4.2.1 Pfizer, Inc Company Information
- 4.2.2 Pfizer, Inc Business Overview
- 4.2.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio
- 4.2.5 Pfizer, Inc Recent Developments
- 4.3 Progenics Pharmaceuticals
- 4.3.1 Progenics Pharmaceuticals Company Information
- 4.3.2 Progenics Pharmaceuticals Business Overview
- 4.3.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio
- 4.3.5 Progenics Pharmaceuticals Recent Developments
- 4.4 IpsenPharma
- 4.4.1 IpsenPharma Company Information
- 4.4.2 IpsenPharma Business Overview
- 4.4.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio
- 4.4.5 IpsenPharma Recent Developments
- 4.5 Hutchison MediPharma Limited
- 4.5.1 Hutchison MediPharma Limited Company Information
- 4.5.2 Hutchison MediPharma Limited Business Overview
- 4.5.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio
- 4.5.5 Hutchison MediPharma Limited Recent Developments
- 4.6 Boehringer Ingelheim International
- 4.6.1 Boehringer Ingelheim International Company Information
- 4.6.2 Boehringer Ingelheim International Business Overview
- 4.6.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio
- 4.6.5 Boehringer Ingelheim International Recent Developments
- 4.7 AVEO Oncology
- 4.7.1 AVEO Oncology Company Information
- 4.7.2 AVEO Oncology Business Overview
- 4.7.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio
- 4.7.5 AVEO Oncology Recent Developments
- 4.8 Advanced Accelerator Applications
- 4.8.1 Advanced Accelerator Applications Company Information
- 4.8.2 Advanced Accelerator Applications Business Overview
- 4.8.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio
- 4.8.5 Advanced Accelerator Applications Recent Developments
5 Global Neuroendocrine Tumors (NETs) Treatment Market Scenario by Region
- 5.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021-2032
- 5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021-2026
- 5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2027-2032
- 5.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2027-2032
- 5.4 North America Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
- 5.4.1 North America Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
- 5.4.3 North America Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
- 5.5.1 Europe Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
- 5.7.1 South America Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
- 5.7.3 South America Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032)
- 6.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032)
- 7.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neuroendocrine Tumors (NETs) Treatment Value Chain Analysis
- 8.1.1 Neuroendocrine Tumors (NETs) Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neuroendocrine Tumors (NETs) Treatment Production Mode & Process
- 8.2 Neuroendocrine Tumors (NETs) Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neuroendocrine Tumors (NETs) Treatment Distributors
- 8.2.3 Neuroendocrine Tumors (NETs) Treatment Customers
9 Global Neuroendocrine Tumors (NETs) Treatment Analyzing Market Dynamics
- 9.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends
- 9.2 Neuroendocrine Tumors (NETs) Treatment Industry Drivers
- 9.3 Neuroendocrine Tumors (NETs) Treatment Industry Opportunities and Challenges
- 9.4 Neuroendocrine Tumors (NETs) Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst